The Practical Answer

Before requesting an FDA Model-Integrated Evidence (MIE) industry meeting, a generic-drug developer should be ready to explain six things clearly: which quantitative model is being used and why it fits the product; how that model integrates with the in vitro and in vivo evidence already available; the specific bioequivalence question the model is meant to help answer; how the modeling work aligns with ICH M15; why the approach is appropriate for this particular dosage form; and what scientific gap the meeting is intended to resolve.

None of these items implies that modeling replaces bioequivalence studies. MIE, as FDA describes it, combines quantitative-medicine approaches with available in vitro and in vivo evidence [S01] — it integrates evidence rather than substituting for it.

What MIE Actually Is

Model-Integrated Evidence (MIE) is an evidentiary approach, not a standalone substitute for clinical or bioequivalence data. FDA describes MIE as quantitative-medicine approaches combined with available in vitro and in vivo evidence [S01]. In the generic-drug context, the modeling methods FDA has associated with MIE discussions include population pharmacokinetics (popPK), physiologically based pharmacokinetic (PBPK) modeling for orally acting and locally acting products, and alignment with product-specific guidance [S01].

The operative word is integrated: the model is one component of a larger evidence package that still includes laboratory and clinical data.

The MIE Industry Meeting Pilot

Separate from the MIE concept itself, FDA operates an MIE industry meeting pilot. This pilot is designed to give generic-drug applicants early scientific interaction with the agency on model-supported bioequivalence approaches [S02]. It is a procedural pathway for obtaining focused FDA feedback on a proposed model-supported bioequivalence approach before a developer commits to major development decisions.

Because the pilot targets early discussion, the meeting request itself should demonstrate that the developer has already done the groundwork: a defined model, a defined question, and a defensible evidence-integration plan.

Where ICH M15 Fits

ICH M15, General Principles of Model-Informed Drug Development, is final FDA guidance as of June 2026. It supplies a general framework covering planning, model evaluation, documentation, regulatory interaction, reporting, and submission of MIDD evidence [S03].

ICH M15 is best understood as the assessment framework a developer should build against — not as a guarantee that any specific model or product will be accepted. A meeting request that maps its modeling plan to M15’s planning, evaluation, and documentation elements is easier for FDA to evaluate than one that does not. This mapping is a best-practice inference, not an FDA-stated requirement.

Product-Specific Acceptance Is Separate

A common point of confusion: ICH M15’s general framework, the MIE concept, and the meeting pilot are all general. They do not, by themselves, establish that a model-supported approach will be accepted for a specific product. Product-specific acceptance depends on product-specific guidance and the strength of the individual evidence package [S01, S03].

Practically, this means a developer should not generalize one model’s success to all dosage forms. A PBPK approach that fits an orally absorbed product may not fit a locally acting one without separate justification — which is precisely the kind of issue an MIE meeting is meant to surface early.

Checklist: What to Explain in an MIE Meeting Request

1. The modeling approach and its scientific basis

Name the specific model type (for example, popPK, oral PBPK, or locally acting PBPK) and explain why it is mechanistically appropriate for the product. State the assumptions the model depends on. The methods listed here are examples associated with FDA’s MIE communications [S01]; they are not endorsed for any specific product.

2. How the model integrates with existing evidence

Show which in vitro and in vivo data the model incorporates and how. FDA describes MIE as modeling combined with available in vitro and in vivo evidence [S01] — make that combination explicit rather than implied. This is the single most important point: MIE integrates with existing evidence; it does not replace it.

3. The specific bioequivalence question

Define the narrow question the model is intended to help answer. The meeting pilot exists for early scientific discussion of model-supported bioequivalence approaches [S02], so the request should identify the exact bioequivalence decision the model supports.

4. Alignment with ICH M15

Map the modeling plan to M15’s framework elements: planning, model evaluation, documentation, regulatory interaction, reporting, and submission [S03]. This is a best-practice inference derived from M15’s scope, not an FDA-stated checklist item.

5. Product-specific justification

Explain why the approach fits this dosage form and product. Do not assume that acceptance of a model for one product transfers to another. Reference applicable product-specific guidance where it exists [S01].

6. The scientific gap the meeting should resolve

State what feedback or alignment you need from FDA and why it cannot be obtained from existing guidance alone. This keeps the meeting focused and productive. This item is a practical inference, not an FDA-stated requirement.

What MIE Does Not Do

To set expectations correctly: MIE does not generally replace in vivo or bioequivalence studies. It is an integration approach. ICH M15 is a general framework, not a product-specific acceptance guarantee. And FDA’s announced MIE virtual workshop (2026-08-27) [S01] is an engagement event, not binding policy.

Medical and Regulatory Scope Disclaimer

This article is an informational explainer about FDA generic-drug regulatory concepts. It is not legal, medical, or regulatory advice, and it does not represent an official FDA position. Regulatory requirements change over time; always consult the current FDA guidance documents and qualified regulatory counsel before making submission decisions. The modeling methods mentioned (popPK, PBPK) are examples associated with FDA’s MIE communications and are not endorsed here for any specific product.

Sources